Two BRAF-mutant PDAC patients showed a significant reduction in carbohydrate antigen 19-9 levels, a PDAC-associated tumor antigen, following co-treatment with dabrafenib plus trametinib [31]. This evidence concerns the gene BRAF and neoplasm.